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Rhabdoid tumors of early infancy are highly aggressive with consequent poor prognosis. Most cases show inactivation of the SMARCB1
(also known as INI1 and hSNF5) tumor suppressor, a core member of the ATP-dependent SWI/SNF chromatin-remodeling complex.
Familial cases, described as rhabdoid tumor predisposition syndrome (RTPS), have been linked to heterozygous SMARCB1 germline
mutations.We identiﬁed inactivation of anothermember of the SWI/SNF chromatin-remodeling complex, its ATPase subunit SMARCA4
(also known as BRG1), due to a SMARCA4/BRG1 germline mutation and loss of heterozygosity by uniparental disomy in the tumor cells
of two sisters with rhabdoid tumors lacking SMARCB1mutations. SMARCA4 is thus a secondmember of the SWI/SNF complex involved
in cancer predisposition. Its general involvement in other tumor entities remains to be established.Rhabdoid tumors (RT) are highly malignant, aggressive,
embryonal neoplasms of early infancy and childhood
(median age at onset: 11 mo) that may originate from
virtually any tissue.1 In the CNS, these tumors are termed
AT/RT (atypical teratoid, rhabdoid tumor), whereas for
the kidney, the term RTK (rhabdoid tumor of kidney) has
been applied. The prognosis of RT is dismal, and despite
recent advances using aggressive, multimodality treatment
schedules,2 the long-term outcome remains doubtful.
The vast majority of RT demonstrate biallelic somatic
inactivation of the SMARCB1 (aliases INI1, hSNF5, BAF47
[MIM *601607]) tumor suppressor within tumor cells.3–5
Different mechanisms contribute to SMARCB1 inactiva-
tion, including gross chromosomal aberrations or loss of
heterozygosity (LOH) of the chromosomal region 22q11.2
containing the SMARCB1 gene, as well as a range of private
point mutations. Remarkably, heterozygous germline
mutations can be observed in up to 20% of patients with
RT,6 including familial cases described as having RT-predis-
position syndrome (RTPS [MIM #609322]). Such germline
mutations predict a fatal course in almost any case.6,7 These
ﬁndings, along with the development of rhabdoid-like
tumors in SMARCB1/þ mice, have qualiﬁed SMARCB1 as
a bona ﬁde tumor suppressor for RT.
SMARCB1 encodes for a core member of the ATP-depen-
dent SWI/SNF chromatin-remodeling complex, a master
regulator of gene expression involved in cancer.8,9 Theoret-
ically, other members of this complex may also be impli-
cated in RTPS. Nevertheless, until now, no germline
mutation in any of the respective gene loci has been
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line or somatic inactivation of the SMARCB1 gene.10
Patient III-2 was diagnosed at 8 mo of age with symptoms
of increased irritability and vomiting. Neuroimaging re-
vealed a mass originating from the right cerebello-pontine
angle, involving the brain stem (Figure 1A). Neurosurgical
biopsy was performed. However, no further treatment was
initiated, because the patient deteriorated rapidly after the
neurosurgical procedure and died of disease progression
only weeks later. Extensive immunohistochemical analysis
by several independent neuropathologists revealed the
diagnosis of an INI1-expressing AT/RT.
Patient III-3 presented at 7 mo of age with increased
abdominal circumference and pain. Imaging studies were
suggestive of a stage IV Wilms tumor with metastases to
the lungsandmediastinum(Figure1B).Becauseof the family
history, a biopsywas performed, yielding the diagnosis of an
INI1-positive RTK. Local disease responded well to an indi-
vidual polychemotherapy regimen enabling a tumor
nephrectomy at 12 mo. However, mediastinal metastases
persisted, and the child died of distant and local disease
before radiotherapy could be initiated, at 18 mo of age.
The family history is unremarkable except for the
maternal grandfather’s death of lung carcinoma and
metastasis to the brain at the age of 66 yrs (Figure 1C).
The father and an unaffected brother of the two children
with RTs are well, without any sign of tumors or schwan-
nomatosis at the time of the writing of this manuscript.
In contrast to the more than 60 SMARCB1-negative RT
cases in our German registry, SMARCB1 expression was
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Figure 1. Synopsis of Clinical and Molecular Data of the Investigated Family
(A) T1-weighted imagingwith contrast demonstrates in axial, coronal, and sagittal planes (from left) a cerebellopontine angle tumorwith
a heterogeneous enhancement pattern and inﬁltration of the brainstem indicative of a highly malignant neoplasm in patient III-2.
(B) MRI and CT imaging of patient III-3 demonstrates a large right ﬂank mass originating from the kidney with metastases to the lungs
(yellow arrows) and mediastinum.
(C) Pedigree of the investigated family and segregation of the SMARCA4 nonsensemutation. The unaffected sibling, individual III-1, was
not available for investigation.
(D) Domain structure of normal SMARCA4 and of the derived p.R1189X truncation mutant. The truncated protein would lack the
C-terminal part of the ATPase subunit, the AT hook, and the Bromo domain.As recently reported,10 extensive molecular studies of
the SMARCB1 locus in this family showed that in concor-
dance with the SMARCB1 expression, SMARCB1mutations
were not detected in tumor cells or leukocytes. Moreover,
ﬂuorescence in situ hybridization (FISH) and array compar-
ative genomic hybridization (CGH) analyses could not
identify chromosomal changes at the SMARCB1 locus,
but they also lacked evidence for chromosomal imbalances
affecting other regions of the tumor genome. Finally,
SMARCB1 haplotyping ruled out SMARCB1 as the causative
gene for the RTs in this family.10 These ﬁndings strongly
pointed to the existence of a yet-unidentiﬁed second
gene locus involved in RTPS in this particular family.
To identify the genetic cause underlying RTPS in this
family, we sequenced the exons and intron-exon borders
of four candidate genes from the core unit of the SWI/
SNF complex—SMARCA4 (MIM *603254), SMARCA2 or
BRM (MIM *600014), SMARCC1 or BAF155 (MIM
*601732), and SMARCC2 or BAF170 (MIM *601734)—in280 The American Journal of Human Genetics 86, 279–284, Februarygermline DNA derived from one of the affected siblings
(III-3). Whereas analyses of the latter three genes revealed
no deviations from the published sequence except allelic
variants of known SNPs, mutation analysis of SMARCA4
identiﬁed the heterozygous nonsense mutation
c.3565C>T (p.Arg1189X), suggesting either a severely
truncated translation product or nonsense-mediated decay
of mRNA as possible consequences (Figure 1D and
Figure 2A). The same mutation was also detected in the
germline of the healthy father but not in the mother. No
germline DNA of patient III-2 was available, but her
AT/RT carried the same mutation in a homozygous state,
suggesting LOH at the SMARCA4 locus in the tumor
(Figure 2A). The same holds true for the RTK of patient
III-3, leading us to investigate the mechanism of LOH in
both RTs (PCR primers and conditions are given in Table
S1, available online).
In line with previous 2.6 K array CGH analyses10 that did
not reveal any chromosomal imbalances in the RT of both12, 2010
Figure 2. SMARCA4 Immunohistochemistry and Molecular Studies
(A) Identiﬁcation of the nonsense mutation p.R1189X (c.3565C>T) in germline DNA, detection of loss of heterozygosity in tumor
DNA (Tu-DNA), and low concentration mutant cDNA obtained by RT PCR from patient III-3’s immortalized B cells compared to the
heterozygous state seen in genomic germline DNA (gDNA).
(B) Copy-neutral loss of heterozygosity in 19p containing the SMARCA4 locus in the RT of patient III-2. 100K SNP array (GeneChip
Human Mapping 100K Set, Affymetrix; Santa Clara, CA, USA) mapping was performed on DNA derived from the RT of patient III-2,
as well as from germline DNA of the father (II-1, for comparison). Analysis of chromosome 19 is displayed with black dots (raw copy-
number data smoothed by a median ﬁlter) and a red line showing copy-number estimations derived from the Copy Number Analyser
for GeneChip (2 ¼ balanced) of the RT of patient III-2 (the gain in 19q derived from a known copy-number variant). Heterozygous calls
are indicated by green dots (RT of III-2) and blue dots (germline DNA of the father, II-1). In contrast to II-1, the RT of III-2 shows loss
of heterozygosity in 19p (gray shaded area, chr19: 341,341–13,425,865 bp), containing the SMARCA4 gene at chr19:10,932,
598–11,033,958 (based on the May 2004 UCSC Genome Browser; hg17).
(C–E) Immunohistochemistry. Tumor cells from both case individuals (C: patient III-2, AT/RT; D: patient III-3, RTK) lack SMARCA4 stain-
ing; immunoreactivity remains restricted to the vasculature. In contrast, 14 sporadic AT/RT (E) (representative staining result) as well as
a panel of embryonal tumors (inset) display nuclear SMARCA4 staining.
(F) Lack of expression of truncated mutant SMARCA4 in immortalized B cell lines of patient III-3 in comparison to B cells of her
mother (II-2) and of a normal control (N). Arrow points to truncated recombinant mutant SMARCA4 (rm) overexpressed in the
SMARCA4-negative cell line NCI H1299. C: nontransfected NCI H1299 as negative control.
(G)Expressionof twonaturallyoccurring splicevariantsofSMARCA4 (onewithout exon27andone includingexon27), bothharboring the
p.R1189Xmutation, in comparison to recombinantWTSMARCA4 indifferent cell lines. 1 and7: nontransfectedHELA cells constitutively
expressing SMARCA4, 2–6: 293-EBNAcells constitutively expressingSMARCA4 (2:mock transfection, 3:WTSMARCA4 long splice variant,
4:mutant SMARCA4 long splice variant, 5:WTSMARCA4 short splice variant, 6:mutant SMARCA4 short splice variant). 8–12:NCI-H1299
cells lacking constitutive SMARCA4 expression (8: mock transfection, 9: WT SMARCA4 long splice variant, 10: mutant SMARCA4 long
splicevariant, 11:WTSMARCA4short splicevariant, 12:mutantSMARCA4short splicevariant). The truncatedmutantp.R1189X fragment
is expressed under a strong cytomegalovirus promoter and is clearly separated from WT SMARCA4 by electrophoresis. Size differences
between the long and the short SMARCA4 splice variants are not visible because of limited electrophoretic resolution.sisters, FISH did not identify a chromosomal aberration of
the SMARCA4 locus in any of the tumors (BAC clones are
listed in Table S2). In contrast, SNP array analysis (Gene-
Chip Human Mapping 100K Set; mapped to hg17, NCBI
build 35) identiﬁed a long stretch (57 SNPs) of copy-neutral
homozygosity in 19p13 (chr19: 341,341–13,425,865 bp)The Americain the RT of patient III-2, suggesting partial uniparental
disomy of the paternal allele to be the cause of LOH in
the tumors (Figure 2B). Remarkably, with the exception
of one other region in chromosome 6q21 (chr6:105,998,
201–107,639,853 bp), this was the only long stretch of
homozygosity in the RT. This, as well as the absence ofn Journal of Human Genetics 86, 279–284, February 12, 2010 281
chromosomal imbalances (except known copy-number
variations), lends further support to SMARCA4 being the
causative gene in this form of RTPS.
After deparafﬁnization and boiling at pH 9 for antigen
retrieval, immunohistochemistry was performed on 2 mm
sections via the Avidin Biotin Complex (ABC) method on
an automated staining system (TechMate, DAKO;
Glostrup,Denmark). For SMARCA4/BRG1 staining, a rabbit
antiserum against BRG1 (catalog number 07-478, 1:2000,
Upstate; Lake Placid, NY, USA) was employed. The speci-
ﬁcity of this antiserum for BRG1 has been documented
previously.11 Tumor cells from both cases lacked SMARCA4
immunoreactivity (Figures 2C and 2D). In contrast, strong
nuclear SMARCA4 staining was observed in all 14 cases of
a series of randomly collected AT/RT, as well as in a panel of
other embryonal tumors, consisting of 40 medulloblas-
tomas, seven primitive neuroectodermal tumors, one
neuroblastoma, and one ependymoblastoma (Figure 2E).
Because the antibody used for immunohistochemistry
detects amino acids 214–279 of human SMARCA4/BRG1,
located N-terminal of the truncating mutation in the
family, the complete absence of detectable protein suggests
nonsense-mediated decay of the mutant transcript. This is
supported by the observation that in lymphoblastoid cells
of patient III-3, the mutant transcript was detected by
RT-PCR only at a much lower level than the wild-type
(WT) allele (see cDNA in Figure 2A) (Primers and RT-PCR
conditions can be provided upon request.)
We also performed an immunoblot of SMARCA4 from
immortalized B cells of patient II-2 and her mother. Cells
were washed twice with Dulbecco’s phosphate-buffered
saline (DPBS), followed by cell lysis in lysis buffer (250 mM
NaCl, 50 mM Tris/HCl pH 8, 0.1% NP40, complete
proteinase inhibitor) and freezing-thawing. The lysate
was centrifuged, and aliquots of the supernatant, each con-
taining 100 mg protein, were applied to a NUPAGE Novex
Bis-Tris Gradient Gel, 4%–12% (Invitrogen). Electropho-
resis was followed by immunoblotting onto Hybond ECL
membrane (GE Healthcare, Freiburg, Germany) with the
use of a monoclonal BRG1 (G-7) antibody (Santa Cruz
Biotechnology; Santa Cruz, CA, USA) as ﬁrst antibody
and a goat-anti-mouse HRP-conjugated antibody (DAKO
Cytomation, Hamburg, Germany) for detection of the
bands by luminescence generated from lumilight substrate
(Roche Diagnostics, Mannheim, Germany). However, we
identiﬁed only a band correlating with the expected size
of the WT protein but not with a mutant truncated trans-
lation product (Figure 2F).
Finally, aiming at further characterizing the mutant
SMARCA4 protein, we carried out recombinant expression
studies of WT and mutant SMARCA4. A SMARCA4 cDNA
((#TC118209, OriGene (Rockville, USA) was subcloned
into the vector pIRESneo2 (C). As this cDNA is a short
SMARCA4 transcript lacking sequence of exon 27 (nucleo-
tide c.3775 - 3893 / p.1259 - 1290) due to alternative
splicing we additionally obtained the full-length cDNA
by in vitro mutagenesis of this clone using the Quick282 The American Journal of Human Genetics 86, 279–284, FebruaryChange mutagenesis kit (Stratagene, La Jolla, USA). The
same method was applied to introduce the patients’ muta-
tion using forward and reverse primers of 40 bp in length
(detailed description of these methods can be provided
upon request).
Two different cell lines, 293-EBNA (Invitrogen, Karlsruhe,
Germany) and NCI-H1299 (CRL-5803, ATCC, USA), the
latter lacking constitutive SMARCA4 expression, were tran-
siently transfected with WT and mutant pIRESneo2-
SMARCA4, respectively, by means of lipofectamine 2000
(Invitrogen) as described previously.12 They were cultured
for 72 hr in high-glucose Dulbecco’s modiﬁed Eagle’s
medium/10% fetal bovine serum and were prepared for
immunoblotting as described above. After overexpression
of mutant SMARCA4 cDNA in either 293 EBNA or NCI-
H1299 cells, we indeed identiﬁed an aberrant band corre-
lating with the expected size of a mutant truncated protein.
No difference in expression of the mutant transcript was
seen between the two splicing variants with and without
exon 27, suggesting that they do not inﬂuence the conse-
quences of the mutation (Figures 2F and 2G). These expres-
sion studies indicate that themutated SMARCA4allele can in
principlebe translated ina truncatedprotein, furthercorrob-
orating that lack of detectable expression in the tumor cells
of the patients is due to nonsense-mediated decay.
Our ﬁndings provide strong evidence that SMARCA4/
BRG1 is a second gene, besides SMARCB1, of the SWI/
SNF chromatin-remodeling complex involved in RTPS.
SMARCA4 has been proposed as a bona ﬁde tumor
suppressor (i) because somatic mutations of SMARCA4
have previously been identiﬁed in epithelial cancer cell
lines such as lung cancer, pancreatic cancer, breast cancer,
and prostate cancer,13–15 though only in a few primary
tumors,14 and (ii) because SMARCA4/þ mice develop
epithelial tumors at a low rate.16 However, RTs have never
been observed in SMARCA4/þ mice, and a causative role
of a single reported germline in-frame 24 bp duplication
of SMARCA4 could not be established in a patient with
lung carcinoma because the respective allele was lost in
the tumor.14 Nevertheless, the association of SMARCA4
to RTPS in the family presented herein is strongly sup-
ported by the following observations:
(1) The RT of both siblings lacked expression of the
SMARCA4 protein.
(2) Both affected sisters carried the same SMARCA4
nonsense mutation.
(3) RT-PCR on the patient’s lymphoblastoid cells and
expression studies indicated nonsense-mediated
decay as the molecular mechanism for the lack of
SMARCA4 expression in the tumors.
(4) Copy-neutral LOH encompassing the SMARCA4
locus in 19p13 was identiﬁed as a ‘‘second hit’’ in
the tumor cells on the background of a balanced
genome.
(5) The classical RT suppressor gene SMARCB1 and
three additional genes coding for core members of12, 2010
the SWI/SNF chromatin-remodeling complex did
not show chromosomal or molecular alterations.
Remarkably, the patients’ father is an as-yet-unaffected
carrier of the same SMARCA4 mutation. This could be
due to incomplete penetrance, as well as to a ‘‘parent of
origin’’ effect of the mutation. Unfortunately, this could
not be further studied because the family rejected testing
of additional members. Nevertheless, incomplete pene-
trance is not truly surprising in RTPS, because it has also
been observed in three of nine published families with
RTPS due to SMARCB1 mutations.17–19 Similarly, incom-
plete penetrance also exists in SMARCB1/þ heterozygous
mice, in which only 6%–15% of animals develop RTs.20,21
These observations of RTPS linked to germline SMARCB1
and, as shown here, SMARCA4mutations, suggest that RT,
similar to other tumors of infancy and early childhood
such as retinoblastoma, neuroblastoma, and nephroblas-
toma, is a developmental disorder that arises in children
in only a limited time frame.22 This is also supported by
the fact that the manifestation of RT occurs at a very early
age, with a median of 5.5 mo in children with SMARCB1
germline mutations and a median of 13 mo in children
without SMARCB1 germline mutations,6 but is very rare
in older children or adults.
SMARCA4 plays a central role in the ATP-dependent
chromatin-remodeling complex by carrying its ATPase
activity. Therefore, its possible involvement in RTPS is a
priori obvious. But until now, no other RT patients had
been diagnosed with SMARCA4 mutations. Furthermore,
in a recent study it was shown that SMARCA4 loss is antag-
onistic to oncogenesis caused by SMARCB1 loss and that
presence of SMARCA4 is essential for tumor formation
caused by SMARCB1 loss in conditional SMARCB1/
mice.23 SMARCA4 loss in our patients with RTs seems to
challenge these observations. However, the situation is
different in our patients because SMARCB1 is present.
This could indicate compensatory mechanisms for
SMARCA4 loss in the oncogenic process. One such mech-
anism could be the replacement of SMARCA4 by
SMARCA2/BRM, another member of the complex that
also carries ATPase activity. However, the two proteins
seem to be mutually exclusive in the complex, suggesting
that they do not act redundantly.8 Additionally, we obvi-
ously cannot rule out a genetic or epigenetic hit additional
to SMARCA4 inactivation that is not detectable with the
applied strategies.
Finally, our ﬁnding that SMARCA4 seems to be not only
dispensable but also rather causative in the manifestation
of RT may also point to a yet-unknown role of SMARCA4
in oncogenesis apart from its ATPase activity in the chro-
matin-remodeling complex.
Besides the role of SMARCA4 as a, to our knowledge,
previously unreported RTPS locus that would affect only
a small number of children, SMARCA4 germline mutations
might also be involved in the manifestation of other
cancers in adults. Incomplete penetrance concerning RT,The Americaas evident in the reported family, does not exclude the
manifestation of other cancers later in life for mutation
carriers. The lack of respective data compromises appro-
priate genetic counseling. Larger systematic studies
screening for SMARCA4 germline mutations in patients
with other cancers lacking SMARCA4 expression are there-
fore desirable.Supplemental Data
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